Chiron Corporation announced this week that the U.S. Food and Drug Administration (FDA) released its findings from the July GMP (good manufacturing practices) inspection of the company’s Liverpool facility which manufactures the FLUVIRIN influenza vaccine. The FDA found the plants’ equipment and processes to be “generally acceptable,” allowing production of the vaccine to continue and Chiron to look to the U.S. market for distribution this flu season pending supplemental approvals from the FDA. In its released statement, Chiron remains hopeful it will be allowed to supply the vaccine and cover expected shortfalls for the 2005-06 influenza season in this country, as well as throughout Europe.